

Anders Jakobsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8191240/anders-jakobsen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

3,724
citations

30
h-index

57
g-index

125
ext. papers

4,424
ext. citations

4.4
avg, IF

5.29
L-index

#	Paper	IF	Citations
118	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	1
117	Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group. <i>Acta Oncologica</i> , 2021 , 1-7	3.2	
116	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021 , 149, 128-133	7.5	4
115	Long-term anorectal function in rectal cancer patients treated with chemoradiotherapy and endorectal brachytherapy. <i>Colorectal Disease</i> , 2021 , 23, 2311-2319	2.1	1
114	Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus-A Population-Based Experience from the Danish Anal Cancer Group. <i>Cancers</i> , 2021 , 13,	6.6	1
113	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 43-50	21.7	31
112	The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 855-865	4.4	2
111	Performance of the EarlyCDT \square Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort. <i>Lung Cancer</i> , 2021 , 158, 85-90	5.9	4
110	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021 , 522, 152-157	6.2	1
109	Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	2
108	Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. <i>Scientific Reports</i> , 2020 , 10, 20113	4.9	3
107	The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting. <i>Gastrointestinal Disorders</i> , 2020 , 2, 378-384	0.8	
106	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , 2020 , 13, 59	5.5	3
105	Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 9-13	2.7	6
104	Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920918472	5.4	13
103	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020 , 59, 652-659	3.2	13
102	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020 , 125, 121-129	7.5	20

101	Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 556-563	4	16
100	Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. <i>Acta Oncologica</i> , 2020 , 59, 298-301	3.2	1
99	Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 751-759	3.5	1
98	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncologica</i> , 2020 , 59, 1016-1023	3.2	2
97	Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta Oncologica</i> , 2020 , 59, 1365-1373	3.3	2
96	Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , 2020 , 40, 5255-5261	2.3	2
95	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , 2019 , 12, 968-972	4.9	10
94	The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 166-173	3.5	9
93	Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
92	MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. 2019 , 2, 885-896		
91	Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	2
90	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019 , 141, 392-396	3.2	29
89	Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 28-33.e3	3.8	5
88	Quantification of NK cell activity using whole blood: Methodological aspects of a new test. <i>Journal of Immunological Methods</i> , 2018 , 458, 21-25	2.5	13
87	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , 2018 , 14, 7-12	2	14
86	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWW): an international multicentre registry study. <i>Lancet, The</i> , 2018 , 391, 2537-2545	40	364
85	Analysis of a gene panel for targeted sequencing of colorectal cancer samples. <i>Oncotarget</i> , 2018 , 9, 9043-9060	3.9	606
84	Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. <i>Acta Oncologica</i> , 2018 , 57, 528-533	3.2	23

83	Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. <i>British Journal of Cancer</i> , 2018 , 119, 1367-1373	8.7	20
82	Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. <i>Scientific Reports</i> , 2017 , 7, 2388	4.9	10
81	The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. <i>Cancer Medicine</i> , 2017 , 6, 928-936	4.8	10
80	The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 180-189	3.2	25
79	Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1842-1849	3.5	27
78	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017 , 22, 1049-1055	5.7	56
77	Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2017 , 14, 201-209	2.6	13
76	The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 1390-8	3.5	14
75	Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. <i>PLoS ONE</i> , 2016 , 11, e0156919	3.7	14
74	MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer. <i>PLoS ONE</i> , 2016 , 11, e0150593	3.7	23
73	Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. <i>Oncology Letters</i> , 2016 , 11, 3967-3974	2.6	11
72	Screening for circulating RAS/RAF mutations by multiplex digital PCR. <i>Clinica Chimica Acta</i> , 2016 , 458, 138-43	6.2	28
71	TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. <i>Tumor Biology</i> , 2015 , 36, 4301-8	2.9	6
70	Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study. <i>Journal of Translational Medicine</i> , 2015 , 13, 10	8.5	13
69	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. <i>Lancet Oncology</i> , 2015 , 16, 919-27	21.7	335
68	Controls to validate plasma samples for cell free DNA quantification. <i>Clinica Chimica Acta</i> , 2015 , 446, 141-6	6.2	46
67	Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. <i>Acta Oncologica</i> , 2015 , 54, 1747-53	3.2	55
66	Elastography and diffusion-weighted MRI in patients with rectal cancer. <i>British Journal of Radiology</i> , 2015 , 88, 20150294	3.4	7

65	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015 , 51, 2678-85	7.5	40
64	Radiation Techniques for Increasing Local Control in the Non-Surgical Management of Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 267-274	1	2
63	Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. <i>Clinica Chimica Acta</i> , 2015 , 439, 97-101	6.2	30
62	Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. <i>Acta Oncologica</i> , 2015 , 54, 179-86	3.2	18
61	Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. <i>PLoS ONE</i> , 2015 , 10, e0108247	3.7	95
60	Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. <i>International Journal of Cancer</i> , 2014 , 135, 2215-22	7.5	67
59	Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. <i>International Journal of Cancer</i> , 2014 , 135, 2984-91	7.5	77
58	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , 2014 , 50, 2611-8	7.5	37
57	Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan. <i>Scandinavian Journal of Gastroenterology</i> , 2014 , 49, 202-8	2.4	38
56	Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 110-8	4	34
55	Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. <i>Oncology Reports</i> , 2014 , 31, 969-74	3.5	28
54	Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. <i>PLoS ONE</i> , 2014 , 9, e96767	3.7	45
53	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014 , 44, 1736-44	4.4	23
52	Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. <i>Radiotherapy and Oncology</i> , 2014 , 113, 352-8	5.3	36
51	Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2238-45	6.1	15
50	The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. <i>Journal of Translational Medicine</i> , 2014 , 12, 254	8.5	15
49	Less extensive surgery compared to extensive surgery: survival seems similar in young women with adult ovarian granulosa cell tumor. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014 , 177, 61-6	2.4	3
48	Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response. <i>Cellular Oncology (Dordrecht)</i> , 2013 , 36, 341-50	7.2	12

47	The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 79, 312-7	5.9	85
46	Immunohistological expression of HIF-1 β , GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer. <i>Apmis</i> , 2013 , 121, 127-38	3.4	8
45	In reply to Fekete. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 213	4	1
44	The influence of tissue ischemia on biomarker expression in colorectal cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013 , 21, 298-307	1.9	6
43	Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. <i>Nuclear Medicine Communications</i> , 2013 , 34, 155-61	1.6	26
42	Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 73-80	3.5	19
41	Limitations of tissue micro array in Duke's B colon cancer. <i>Apmis</i> , 2012 , 120, 819-27	3.4	2
40	The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2012 , 12, 83	4.8	47
39	Single nucleotide polymorphisms in the HIF-1 β gene and chemoradiotherapy of locally advanced rectal cancer. <i>Oncology Letters</i> , 2012 , 4, 1056-1060	2.6	4
38	Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 949-54	4	81
37	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , 2012 , 5, 23	5.5	24
36	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. <i>Clinical Cancer Research</i> , 2012 , 18, 1177-85	12.9	214
35	Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. <i>Pharmacogenomics</i> , 2012 , 13, 763-70	2.6	15
34	The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 715-20	3	42
33	Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up. <i>Pathology Research International</i> , 2012 , 2012, 851432		9
32	The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 1474-82	3.5	21
31	Transrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5021-6	5.6	20
30	The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011 , 4, 12-18		3

29	Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 1040-7	3.5	40
28	Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. <i>Journal of Oncology</i> , 2011 , 2011, 620523	4.5	63
27	Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. <i>Oncology Letters</i> , 2011 , 2, 1101-1106	2.6	23
26	EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011 , 11, 107	4.8	15
25	A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. <i>Acta Oncologica</i> , 2011 , 50, 448-54	3.2	17
24	Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. <i>Pharmacogenomics</i> , 2011 , 12, 1681-93	2.6	21
23	Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 1592-600	3.5	30
22	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIIG). <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 419-23	3.5	400
21	Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 589-600	3.5	9
20	The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer. <i>Cancers</i> , 2010 , 2, 1405-18	6.6	9
19	Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010 , 456, 251-60	5.1	39
18	The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 751-8	4.9	23
17	Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , 2010 , 10, 185	4.8	5
16	The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 820-5	3.5	59
15	Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 641-5	3	7
14	Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 578-84	3.5	27
13	Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008 , 1, 127-134		4
12	Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer. <i>Cancer Investigation</i> , 2008 , 26, 583-9	2.1	10

11	Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 3278-82	12.9	26
10	Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 440-6	2.4	23
9	PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2008 , 51, 21-5	3.1	68
8	A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. <i>International Journal of Colorectal Disease</i> , 2008 , 23, 251-5	3	20
7	The prognostic importance of thymidylate gene polymorphism in colon cancer stage II. <i>International Journal of Colorectal Disease</i> , 2008 , 23, 1267	3	
6	Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. <i>Diseases of the Colon and Rectum</i> , 2007 , 50, 1363-9	3.1	33
5	Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. <i>Acta Oncologica</i> , 2007 , 46, 1113-7	3.2	30
4	Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 461-5	4	56
3	Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/5-fluorouracil in recurrent cervical cancer. <i>Gynecologic and Obstetric Investigation</i> , 2005 , 59, 126-9	2.5	17
2	Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. <i>Gynecologic Oncology</i> , 2001 , 81, 456-60	4.9	74
1	A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer. <i>Gynecologic Oncology</i> , 1994 , 55, 123-5	4.9	9